Market Overview

Glaukos Has 84% Upside Potential In 2018, According To Cantor

Glaukos Has 84% Upside Potential In 2018, According To Cantor
Related GKOS
The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Glaukos' iStent shows long-term benefit in glaucom study (Seeking Alpha)

Glaukos Corp (NYSE: GKOS) announced the submission of a pre-market approval application for its iStent inject device on Wednesday.

The Analyst

Cantor Fitzgerald's Elemer Piros maintains an Overweight rating on Glaukos' stock with a price target boosted from $48 to $60.

The Thesis

Glaukos' filing consists of results from a two-year long pivotal trial that compared the device with cataract surgery alone among 505 patients, Piros said in a note. (See the analyst's track record here.)

The results achieved Glaukos' primary endpoint of lowering intraocular pressure by 20 percent or greater, according to Cantor Fitzgerald.

Now that the company is proceeding with the approval process, investors may want to reset their expectations for 2018 commercially and acknowledge that the iDose franchise is a major long-term growth driver, Piros said. 

Based on the analyst's estimate, the iDose franchise could achieve revenues of $1 billion at peak penetration of 15 percent in the glaucoma drug treatment landscape, the analyst said.

"While questions over competition and reimbursement dominated the last few quarters, we view the headwinds as manageable and most importantly believe investors underappreciate the long-term potential of iDose and the R&D pipeline," Piros said. "Considering that the iStent franchise drives Glaukos' current R&D pipeline, we bring to greater focus the potential of iDose with our newly introduced market model in ocular hypertension and open angle glaucoma."

Price Action

Shares of Glaukos were trading slightly down at $26.05 at the time of publication. 

Related Links:

The Market In 5 Minutes: Fake Comments, Crypto For IoT, Apple Lawsuits, Retail Sales

5 Stocks To Watch For December 27, 2017

An iStent trabecular micro-bypass. Photo courtesy of Glaukos.

Latest Ratings for GKOS

Sep 2018BMO CapitalMaintainsMarket PerformMarket Perform
Aug 2018BMO CapitalMaintainsMarket PerformMarket Perform
Aug 2018JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for GKOS
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Elemer Piros iDose Istent InjectAnalyst Color Price Target Reiteration Analyst Ratings Best of Benzinga


Related Articles (GKOS)

View Comments and Join the Discussion!

Latest Ratings

SYBXChardan CapitalInitiates Coverage On20.0
GEJP MorganUpgrades6.0
FEYEMorgan StanleyDowngrades21.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Vetr Picks Tesla's Slide As A Buying Opportunity

Tax Cut Sends Refiners ETF To Record Highs